Skip to content

Perspectives

Read before your next deal.

Industry evidence on life sciences partnerships and valuation, with Isabella Visconti’s view on what it means now.

  • Slide 1: Better visibility, better decisions, better deals. The Alliance Integrator series.
  • Slide 2: The issue is visibility. Market access data rarely reaches the valuation stage. US first-year payer rejection of new launches: from 40% to 64% in six years (IQVIA, 2025). Market access: the most cited reason launches miss expectations (Deloitte, 2023). Under MFN, a low-price concession abroad can depress the asset’s US price ceiling (Skadden, 2026).
  • Slide 3: Known at valuation, it is a negotiating position. Known after launch, it is a write-down. The Alliance Integrator is designed to give that visibility at valuation: market access, MFN exposure and pricing, before you engage, spend or commit. Better visibility. Better decisions. Better deals.

The Alliance Integrator series

Better visibility, better decisions, better deals.

Deal risks surface too late, when renegotiation or exit are the only options left.

The issue is visibility: market access data rarely reaches the valuation stage.

Known at valuation, it is a negotiating position. Known after launch, it is a write-down.

Sources on the slides: IQVIA, 2025; Deloitte, 2023; Skadden, 2026.

Read the post on LinkedIn Follow on LinkedIn

Start a conversation

Book a consultation, or register for an Integrator demo. Your request comes straight to us.

Request a demo Book a call

Book a call opens Cal.eu, which has its own privacy notice.

info@vamswitzerland.com